Symphogen's Series F - II Round

Symphogen raised a round of funding on May 02, 2013.

Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market. The company has advanced the fr…

Articles about Symphogen's Series F - II Round: